clinical trial · NCT07316062
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
AstraZeneca·—·not yet recruiting·n = 3,000
Non-Small-Cell Lung
brief summary
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
started
Apr 15, 2026
primary completion
Apr 30, 2029
completion
Apr 30, 2029
last updated
Jan 5, 2026
detailed description
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
official title
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol